U.S. Physical Therapy, Inc. (USPH) Stock Competitors & Peer Comparison
See (USPH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| USPH | $65.55 | -0.02% | 996.9M | 131.01 | $0.50 | +2.79% |
| HCA | $396.81 | +2.49% | 86.5B | 13.43 | $29.04 | +0.76% |
| THC | $182.51 | +4.49% | 15.4B | 9.31 | $19.23 | N/A |
| DVA | $208.75 | +0.04% | 13.5B | 20.23 | $10.37 | N/A |
| SOLV | $76.01 | -3.63% | 13.3B | 9.41 | $8.17 | N/A |
| FMS | $23.81 | +3.41% | 12.6B | 12.41 | $1.89 | +3.68% |
| EHC | $99.96 | -1.49% | 9.9B | 17.02 | $5.84 | +0.75% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| UHS | $147.40 | +0.67% | 9.1B | 6.10 | $23.95 | +0.55% |
| ENSG | $155.78 | +4.29% | 8.8B | 24.55 | $6.14 | +0.17% |
Stock Comparison
USPH vs HCA Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, HCA has a market cap of 86.5B. Regarding current trading prices, USPH is priced at $65.55, while HCA trades at $396.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas HCA's P/E ratio is 13.43. In terms of profitability, USPH's ROE is +0.00%, compared to HCA's ROE of -1.23%. Regarding short-term risk, USPH is less volatile compared to HCA. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check HCA's competition here
USPH vs THC Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, THC has a market cap of 15.4B. Regarding current trading prices, USPH is priced at $65.55, while THC trades at $182.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas THC's P/E ratio is 9.31. In terms of profitability, USPH's ROE is +0.00%, compared to THC's ROE of +0.41%. Regarding short-term risk, USPH is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check THC's competition here
USPH vs DVA Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, DVA has a market cap of 13.5B. Regarding current trading prices, USPH is priced at $65.55, while DVA trades at $208.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas DVA's P/E ratio is 20.23. In terms of profitability, USPH's ROE is +0.00%, compared to DVA's ROE of -1.33%. Regarding short-term risk, USPH is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check DVA's competition here
USPH vs SOLV Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, SOLV has a market cap of 13.3B. Regarding current trading prices, USPH is priced at $65.55, while SOLV trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas SOLV's P/E ratio is 9.41. In terms of profitability, USPH's ROE is +0.00%, compared to SOLV's ROE of +0.31%. Regarding short-term risk, USPH is less volatile compared to SOLV. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check SOLV's competition here
USPH vs FMS Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, FMS has a market cap of 12.6B. Regarding current trading prices, USPH is priced at $65.55, while FMS trades at $23.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas FMS's P/E ratio is 12.41. In terms of profitability, USPH's ROE is +0.00%, compared to FMS's ROE of +0.07%. Regarding short-term risk, USPH is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check FMS's competition here
USPH vs EHC Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, EHC has a market cap of 9.9B. Regarding current trading prices, USPH is priced at $65.55, while EHC trades at $99.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas EHC's P/E ratio is 17.02. In terms of profitability, USPH's ROE is +0.00%, compared to EHC's ROE of +0.25%. Regarding short-term risk, USPH is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check EHC's competition here
USPH vs OSH Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, USPH is priced at $65.55, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas OSH's P/E ratio is -17.65. In terms of profitability, USPH's ROE is +0.00%, compared to OSH's ROE of +4.64%. Regarding short-term risk, USPH is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check OSH's competition here
USPH vs UHS Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, UHS has a market cap of 9.1B. Regarding current trading prices, USPH is priced at $65.55, while UHS trades at $147.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas UHS's P/E ratio is 6.10. In terms of profitability, USPH's ROE is +0.00%, compared to UHS's ROE of +0.21%. Regarding short-term risk, USPH is less volatile compared to UHS. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check UHS's competition here
USPH vs ENSG Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, ENSG has a market cap of 8.8B. Regarding current trading prices, USPH is priced at $65.55, while ENSG trades at $155.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas ENSG's P/E ratio is 24.55. In terms of profitability, USPH's ROE is +0.00%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, USPH is less volatile compared to ENSG. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check ENSG's competition here
USPH vs CHE Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, CHE has a market cap of 5.6B. Regarding current trading prices, USPH is priced at $65.55, while CHE trades at $431.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas CHE's P/E ratio is 23.14. In terms of profitability, USPH's ROE is +0.00%, compared to CHE's ROE of +0.25%. Regarding short-term risk, USPH is less volatile compared to CHE. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CHE's competition here
USPH vs LHCG Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, USPH is priced at $65.55, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas LHCG's P/E ratio is 82.83. In terms of profitability, USPH's ROE is +0.00%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, USPH is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check LHCG's competition here
USPH vs MMED Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, MMED has a market cap of 4.2B. Regarding current trading prices, USPH is priced at $65.55, while MMED trades at $14.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas MMED's P/E ratio is -11.81. In terms of profitability, USPH's ROE is +0.00%, compared to MMED's ROE of -0.09%. Regarding short-term risk, USPH is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check MMED's competition here
USPH vs OPCH Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, OPCH has a market cap of 3.3B. Regarding current trading prices, USPH is priced at $65.55, while OPCH trades at $21.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas OPCH's P/E ratio is 16.59. In terms of profitability, USPH's ROE is +0.00%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, USPH is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check OPCH's competition here
USPH vs LFST Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, LFST has a market cap of 3.3B. Regarding current trading prices, USPH is priced at $65.55, while LFST trades at $8.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas LFST's P/E ratio is 143.17. In terms of profitability, USPH's ROE is +0.00%, compared to LFST's ROE of +0.02%. Regarding short-term risk, USPH is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check LFST's competition here
USPH vs AMED Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, USPH is priced at $65.55, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas AMED's P/E ratio is 39.30. In terms of profitability, USPH's ROE is +0.00%, compared to AMED's ROE of +0.09%. Regarding short-term risk, USPH is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check AMED's competition here
USPH vs BKD Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, BKD has a market cap of 3.3B. Regarding current trading prices, USPH is priced at $65.55, while BKD trades at $13.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas BKD's P/E ratio is -15.65. In terms of profitability, USPH's ROE is +0.00%, compared to BKD's ROE of +401.19%. Regarding short-term risk, USPH is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check BKD's competition here
USPH vs NHC Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, NHC has a market cap of 3.1B. Regarding current trading prices, USPH is priced at $65.55, while NHC trades at $196.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas NHC's P/E ratio is 24.87. In terms of profitability, USPH's ROE is +0.00%, compared to NHC's ROE of +0.12%. Regarding short-term risk, USPH is less volatile compared to NHC. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check NHC's competition here
USPH vs ACHC Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, ACHC has a market cap of 2.3B. Regarding current trading prices, USPH is priced at $65.55, while ACHC trades at $25.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas ACHC's P/E ratio is -2.05. In terms of profitability, USPH's ROE is +0.00%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, USPH is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check ACHC's competition here
USPH vs SEM Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, SEM has a market cap of 2.1B. Regarding current trading prices, USPH is priced at $65.55, while SEM trades at $16.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas SEM's P/E ratio is 15.56. In terms of profitability, USPH's ROE is +0.00%, compared to SEM's ROE of +0.08%. Regarding short-term risk, USPH is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check SEM's competition here
USPH vs MD Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, MD has a market cap of 2B. Regarding current trading prices, USPH is priced at $65.55, while MD trades at $24.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas MD's P/E ratio is 11.83. In terms of profitability, USPH's ROE is +0.00%, compared to MD's ROE of +0.20%. Regarding short-term risk, USPH is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check MD's competition here
USPH vs SGRY Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, SGRY has a market cap of 2B. Regarding current trading prices, USPH is priced at $65.55, while SGRY trades at $15.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas SGRY's P/E ratio is -25.64. In terms of profitability, USPH's ROE is +0.00%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, USPH is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check SGRY's competition here
USPH vs AGL Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, AGL has a market cap of 1.9B. Regarding current trading prices, USPH is priced at $65.55, while AGL trades at $111.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas AGL's P/E ratio is -5.07. In terms of profitability, USPH's ROE is +0.00%, compared to AGL's ROE of -1.46%. Regarding short-term risk, USPH is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AGL's competition here
USPH vs ASTH Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, ASTH has a market cap of 1.9B. Regarding current trading prices, USPH is priced at $65.55, while ASTH trades at $38.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas ASTH's P/E ratio is 62.92. In terms of profitability, USPH's ROE is +0.00%, compared to ASTH's ROE of +0.04%. Regarding short-term risk, USPH is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check ASTH's competition here
USPH vs AMEH Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, USPH is priced at $65.55, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas AMEH's P/E ratio is 39.25. In terms of profitability, USPH's ROE is +0.00%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, USPH is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AMEH's competition here
USPH vs ADUS Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, ADUS has a market cap of 1.8B. Regarding current trading prices, USPH is priced at $65.55, while ADUS trades at $95.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas ADUS's P/E ratio is 17.50. In terms of profitability, USPH's ROE is +0.00%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, USPH is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check ADUS's competition here
USPH vs AVAH Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, AVAH has a market cap of 1.6B. Regarding current trading prices, USPH is priced at $65.55, while AVAH trades at $7.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas AVAH's P/E ratio is 5.98. In terms of profitability, USPH's ROE is +0.00%, compared to AVAH's ROE of +2.41%. Regarding short-term risk, USPH is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AVAH's competition here
USPH vs HCSG Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, HCSG has a market cap of 1.5B. Regarding current trading prices, USPH is priced at $65.55, while HCSG trades at $22.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas HCSG's P/E ratio is 23.46. In terms of profitability, USPH's ROE is +0.00%, compared to HCSG's ROE of +0.14%. Regarding short-term risk, USPH is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check HCSG's competition here
USPH vs ARDT Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, ARDT has a market cap of 1.4B. Regarding current trading prices, USPH is priced at $65.55, while ARDT trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas ARDT's P/E ratio is 9.99. In terms of profitability, USPH's ROE is +0.00%, compared to ARDT's ROE of +0.09%. Regarding short-term risk, USPH is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check ARDT's competition here
USPH vs INNV Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, INNV has a market cap of 1.2B. Regarding current trading prices, USPH is priced at $65.55, while INNV trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas INNV's P/E ratio is -114.50. In terms of profitability, USPH's ROE is +0.00%, compared to INNV's ROE of -0.09%. Regarding short-term risk, USPH is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check INNV's competition here
USPH vs BKDT Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, USPH is priced at $65.55, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas BKDT's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to BKDT's ROE of +401.19%. Regarding short-term risk, USPH is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check BKDT's competition here
USPH vs AMN Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, AMN has a market cap of 1.2B. Regarding current trading prices, USPH is priced at $65.55, while AMN trades at $31.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas AMN's P/E ratio is -35.90. In terms of profitability, USPH's ROE is +0.00%, compared to AMN's ROE of -0.05%. Regarding short-term risk, USPH is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AMN's competition here
USPH vs PNTG Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, USPH is priced at $65.55, while PNTG trades at $33.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas PNTG's P/E ratio is 38.42. In terms of profitability, USPH's ROE is +0.00%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, USPH is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check PNTG's competition here
USPH vs CMPS Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, CMPS has a market cap of 1.1B. Regarding current trading prices, USPH is priced at $65.55, while CMPS trades at $11.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas CMPS's P/E ratio is -3.75. In terms of profitability, USPH's ROE is +0.00%, compared to CMPS's ROE of -1.51%. Regarding short-term risk, USPH is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CMPS's competition here
USPH vs TALK Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, TALK has a market cap of 871.1M. Regarding current trading prices, USPH is priced at $65.55, while TALK trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas TALK's P/E ratio is 130.00. In terms of profitability, USPH's ROE is +0.00%, compared to TALK's ROE of +0.01%. Regarding short-term risk, USPH is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check TALK's competition here
USPH vs FSHCX Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, FSHCX has a market cap of 806.7M. Regarding current trading prices, USPH is priced at $65.55, while FSHCX trades at $114.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas FSHCX's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to FSHCX's ROE of N/A. Regarding short-term risk, USPH is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check FSHCX's competition here
USPH vs TALKW Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, TALKW has a market cap of 770.1M. Regarding current trading prices, USPH is priced at $65.55, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas TALKW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to TALKW's ROE of +0.01%. Regarding short-term risk, USPH is more volatile compared to TALKW. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check TALKW's competition here
USPH vs EHAB Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, USPH is priced at $65.55, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas EHAB's P/E ratio is -197.14. In terms of profitability, USPH's ROE is +0.00%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, USPH is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check EHAB's competition here
USPH vs SNDA Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, SNDA has a market cap of 691.6M. Regarding current trading prices, USPH is priced at $65.55, while SNDA trades at $34.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas SNDA's P/E ratio is -5.92. In terms of profitability, USPH's ROE is +0.00%, compared to SNDA's ROE of -0.35%. Regarding short-term risk, USPH is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check SNDA's competition here
USPH vs GMRS Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, GMRS has a market cap of 547.9M. Regarding current trading prices, USPH is priced at $65.55, while GMRS trades at $12.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas GMRS's P/E ratio is 6.22. In terms of profitability, USPH's ROE is +0.00%, compared to GMRS's ROE of N/A. Regarding short-term risk, USPH is less volatile compared to GMRS. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check GMRS's competition here
USPH vs TOI Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, TOI has a market cap of 517.9M. Regarding current trading prices, USPH is priced at $65.55, while TOI trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas TOI's P/E ratio is -14.80. In terms of profitability, USPH's ROE is +0.00%, compared to TOI's ROE of +3.27%. Regarding short-term risk, USPH is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check TOI's competition here
USPH vs MCTA Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, USPH is priced at $65.55, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas MCTA's P/E ratio is 419.36. In terms of profitability, USPH's ROE is +0.00%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, USPH is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check MCTA's competition here
USPH vs CCRN Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, CCRN has a market cap of 434.7M. Regarding current trading prices, USPH is priced at $65.55, while CCRN trades at $13.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas CCRN's P/E ratio is -4.32. In terms of profitability, USPH's ROE is +0.00%, compared to CCRN's ROE of -0.27%. Regarding short-term risk, USPH is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check CCRN's competition here
USPH vs CYH Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, CYH has a market cap of 434M. Regarding current trading prices, USPH is priced at $65.55, while CYH trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas CYH's P/E ratio is 0.90. In terms of profitability, USPH's ROE is +0.00%, compared to CYH's ROE of +0.06%. Regarding short-term risk, USPH is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CYH's competition here
USPH vs AUNA Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, AUNA has a market cap of 370.1M. Regarding current trading prices, USPH is priced at $65.55, while AUNA trades at $5.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas AUNA's P/E ratio is 18.52. In terms of profitability, USPH's ROE is +0.00%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, USPH is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AUNA's competition here
USPH vs AIRS Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, AIRS has a market cap of 358.4M. Regarding current trading prices, USPH is priced at $65.55, while AIRS trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas AIRS's P/E ratio is -29.88. In terms of profitability, USPH's ROE is +0.00%, compared to AIRS's ROE of -0.12%. Regarding short-term risk, USPH is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AIRS's competition here
USPH vs CSU Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, USPH is priced at $65.55, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas CSU's P/E ratio is 0.67. In terms of profitability, USPH's ROE is +0.00%, compared to CSU's ROE of -0.51%. Regarding short-term risk, USPH is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CSU's competition here
USPH vs JYNT Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, JYNT has a market cap of 131.4M. Regarding current trading prices, USPH is priced at $65.55, while JYNT trades at $9.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas JYNT's P/E ratio is 102.44. In terms of profitability, USPH's ROE is +0.00%, compared to JYNT's ROE of +0.17%. Regarding short-term risk, USPH is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check JYNT's competition here
USPH vs NAKAW Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, USPH is priced at $65.55, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas NAKAW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to NAKAW's ROE of -0.85%. Regarding short-term risk, USPH is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check NAKAW's competition here
USPH vs BTMD Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, BTMD has a market cap of 99.2M. Regarding current trading prices, USPH is priced at $65.55, while BTMD trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas BTMD's P/E ratio is 5.23. In terms of profitability, USPH's ROE is +0.00%, compared to BTMD's ROE of -0.23%. Regarding short-term risk, USPH is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check BTMD's competition here
USPH vs FVE Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, USPH is priced at $65.55, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas FVE's P/E ratio is -5.64. In terms of profitability, USPH's ROE is +0.00%, compared to FVE's ROE of -0.15%. Regarding short-term risk, USPH is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check FVE's competition here
USPH vs KDLYW Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, USPH is priced at $65.55, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas KDLYW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to KDLYW's ROE of -0.85%. Regarding short-term risk, USPH is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check KDLYW's competition here
USPH vs DCGO Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, DCGO has a market cap of 57.2M. Regarding current trading prices, USPH is priced at $65.55, while DCGO trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas DCGO's P/E ratio is -0.31. In terms of profitability, USPH's ROE is +0.00%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, USPH is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check DCGO's competition here
USPH vs ALR Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, USPH is priced at $65.55, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas ALR's P/E ratio is -1.11. In terms of profitability, USPH's ROE is +0.00%, compared to ALR's ROE of -0.15%. Regarding short-term risk, USPH is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check ALR's competition here
USPH vs PIII Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, PIII has a market cap of 37.9M. Regarding current trading prices, USPH is priced at $65.55, while PIII trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas PIII's P/E ratio is -0.30. In terms of profitability, USPH's ROE is +0.00%, compared to PIII's ROE of +1.85%. Regarding short-term risk, USPH is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check PIII's competition here
USPH vs IMAC Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, USPH is priced at $65.55, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas IMAC's P/E ratio is -2.27. In terms of profitability, USPH's ROE is +0.00%, compared to IMAC's ROE of +5.81%. Regarding short-term risk, USPH is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check IMAC's competition here
USPH vs PIIIW Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, PIIIW has a market cap of 32.1M. Regarding current trading prices, USPH is priced at $65.55, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, USPH's ROE is +0.00%, compared to PIIIW's ROE of +1.85%. Regarding short-term risk, USPH is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check PIIIW's competition here
USPH vs CCEL Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, CCEL has a market cap of 29.3M. Regarding current trading prices, USPH is priced at $65.55, while CCEL trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas CCEL's P/E ratio is -11.37. In terms of profitability, USPH's ROE is +0.00%, compared to CCEL's ROE of +0.16%. Regarding short-term risk, USPH is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CCEL's competition here
USPH vs CANO-WT Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, USPH is priced at $65.55, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, USPH is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CANO-WT's competition here
USPH vs AIH Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, USPH is priced at $65.55, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas AIH's P/E ratio is -2.78. In terms of profitability, USPH's ROE is +0.00%, compared to AIH's ROE of +1.16%. Regarding short-term risk, USPH is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AIH's competition here
USPH vs CANO Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, USPH is priced at $65.55, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas CANO's P/E ratio is -0.01. In terms of profitability, USPH's ROE is +0.00%, compared to CANO's ROE of -1.49%. Regarding short-term risk, USPH is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CANO's competition here
USPH vs FTRP Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, USPH is priced at $65.55, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas FTRP's P/E ratio is -1.22. In terms of profitability, USPH's ROE is +0.00%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, USPH is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check FTRP's competition here
USPH vs AMS Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, AMS has a market cap of 9.7M. Regarding current trading prices, USPH is priced at $65.55, while AMS trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas AMS's P/E ratio is -6.68. In terms of profitability, USPH's ROE is +0.00%, compared to AMS's ROE of -0.06%. Regarding short-term risk, USPH is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AMS's competition here
USPH vs MODV Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, USPH is priced at $65.55, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas MODV's P/E ratio is -0.03. In terms of profitability, USPH's ROE is +0.00%, compared to MODV's ROE of +1.84%. Regarding short-term risk, USPH is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check MODV's competition here
USPH vs GBNH Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, USPH is priced at $65.55, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas GBNH's P/E ratio is -0.06. In terms of profitability, USPH's ROE is +0.00%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, USPH is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check GBNH's competition here
USPH vs RHE Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, USPH is priced at $65.55, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas RHE's P/E ratio is -1.79. In terms of profitability, USPH's ROE is +0.00%, compared to RHE's ROE of -0.36%. Regarding short-term risk, USPH is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check RHE's competition here
USPH vs RHE-PA Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, USPH is priced at $65.55, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, USPH's ROE is +0.00%, compared to RHE-PA's ROE of +2.11%. Regarding short-term risk, USPH is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check RHE-PA's competition here
USPH vs TOIIW Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, TOIIW has a market cap of 4.2M. Regarding current trading prices, USPH is priced at $65.55, while TOIIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas TOIIW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to TOIIW's ROE of +3.27%. Regarding short-term risk, USPH is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check TOIIW's competition here
USPH vs IMACW Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, USPH is priced at $65.55, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas IMACW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, USPH is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check IMACW's competition here
USPH vs CCM Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, CCM has a market cap of 633.4K. Regarding current trading prices, USPH is priced at $65.55, while CCM trades at $4.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas CCM's P/E ratio is -1.39. In terms of profitability, USPH's ROE is +0.00%, compared to CCM's ROE of +0.07%. Regarding short-term risk, USPH is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CCM's competition here
USPH vs MNDR Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, MNDR has a market cap of 585.3K. Regarding current trading prices, USPH is priced at $65.55, while MNDR trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas MNDR's P/E ratio is -0.27. In terms of profitability, USPH's ROE is +0.00%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, USPH is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check MNDR's competition here
USPH vs NIVF Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, NIVF has a market cap of 330.4K. Regarding current trading prices, USPH is priced at $65.55, while NIVF trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas NIVF's P/E ratio is 0.02. In terms of profitability, USPH's ROE is +0.00%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, USPH is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check NIVF's competition here
USPH vs NIVFW Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, NIVFW has a market cap of 45.9K. Regarding current trading prices, USPH is priced at $65.55, while NIVFW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas NIVFW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, USPH is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check NIVFW's competition here
USPH vs NFH Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, NFH has a market cap of 0. Regarding current trading prices, USPH is priced at $65.55, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas NFH's P/E ratio is -19.75. In terms of profitability, USPH's ROE is +0.00%, compared to NFH's ROE of -0.06%. Regarding short-term risk, USPH is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check NFH's competition here
USPH vs ATIP-WT Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, USPH is priced at $65.55, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, USPH is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check ATIP-WT's competition here
USPH vs TVTY Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, TVTY has a market cap of 0. Regarding current trading prices, USPH is priced at $65.55, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas TVTY's P/E ratio is 19.06. In terms of profitability, USPH's ROE is +0.00%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, USPH is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check TVTY's competition here
USPH vs TLMD Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, TLMD has a market cap of 0. Regarding current trading prices, USPH is priced at $65.55, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas TLMD's P/E ratio is -1.60. In terms of profitability, USPH's ROE is +0.00%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, USPH is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check TLMD's competition here
USPH vs TLMDW Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, USPH is priced at $65.55, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas TLMDW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, USPH is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check TLMDW's competition here
USPH vs DVCR Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, DVCR has a market cap of 0. Regarding current trading prices, USPH is priced at $65.55, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas DVCR's P/E ratio is 28.34. In terms of profitability, USPH's ROE is +0.00%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, USPH is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check DVCR's competition here
USPH vs AFAM Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, AFAM has a market cap of 0. Regarding current trading prices, USPH is priced at $65.55, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas AFAM's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, USPH is less volatile compared to AFAM. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AFAM's competition here
USPH vs KND Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, KND has a market cap of 0. Regarding current trading prices, USPH is priced at $65.55, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas KND's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to KND's ROE of -0.53%. Regarding short-term risk, USPH is more volatile compared to KND. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check KND's competition here
USPH vs SLHG Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, SLHG has a market cap of 0. Regarding current trading prices, USPH is priced at $65.55, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas SLHG's P/E ratio is -1.48. In terms of profitability, USPH's ROE is +0.00%, compared to SLHG's ROE of N/A. Regarding short-term risk, USPH is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check SLHG's competition here
USPH vs SLHGP Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, USPH is priced at $65.55, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, USPH's ROE is +0.00%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, USPH is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check SLHGP's competition here
USPH vs HNGR Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, HNGR has a market cap of 0. Regarding current trading prices, USPH is priced at $65.55, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas HNGR's P/E ratio is 19.71. In terms of profitability, USPH's ROE is +0.00%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, USPH is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check HNGR's competition here
USPH vs DCGOW Comparison June 2026
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 996.9M. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, USPH is priced at $65.55, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 131.01, whereas DCGOW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.00%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, USPH is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check DCGOW's competition here